51206-40-7

Basic information

• Product Name: 1,4-DIBROMOISOQUINOLINE
• Synonyms: 1,4-DIBROMOISOQUINOLINE;Isoquinoline, 1,4-dibromo-
• CAS NO: 51206-40-7
• Molecular Formula: C₉H₅Br₂N
• Molecular Weight: 286.95
• Mol File: 51206-40-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 352.519 °C at 760 mmHg
• Flash Point: 166.998 °C
• Appearance: /
• Density: 1.923
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.02±0.31(Predicted)
• CAS DataBase Reference: 1,4-DIBROMOISOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DIBROMOISOQUINOLINE(51206-40-7)
• EPA Substance Registry System: 1,4-DIBROMOISOQUINOLINE(51206-40-7)

Safety Data

• Hazardous Substances Data: 51206-40-7(Hazardous Substances Data)

Usage

General Description

1,4-Dibromoisoquinoline is a chemical compound and an important structural component in various chemical derivatives used in pharmaceutical and materials chemistry. As an organic bromine compound, it has two bromo groups bonded to an isoquinoline structure, a nitrogen-based organic compound with two fused benzene rings. It is particularly valuable for its potential in forming Br?nsted acid catalysts. Its properties and effects are still being researched for utilization in different areas, including medicinal drug development. It should be handled with care due to its corrosive properties and potential health hazards upon exposure.

Upstream product

• 1532-71-4 1-bromoisoquinoline 
• 3749-21-1 4-bromoisoquinoline N-oxide 
• 491-30-5 1-isoquinolone 
• 491-30-5 1-hydroxyisoquinoline 

Downstream Products

• 927800-97-3 4-bromo-1-iodoisoquinoline 
• 332012-28-9 1-(4-chlorophenylamino)-4-(pyridin-4-ylthio)isoquinoline 
• 332013-04-4 C₂₂H₁₆F₃N₃S 
• 332013-37-3 1-(4-chloroaniline)-4-bromoisoquinoline 

Relevant articles and documents

1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION

Disclosed herein are compounds that can act as inhibitors of the Kelch-like ECH- associated protein 1/nuclear factor (erythroid-derived 2)-like 2 ("KEAP1/NRF2") protein- protein interaction, and methods of using the compounds to treat and prevent diseases and disorders, such as COPD, multiple sclerosis, and diabetes, and in the promotion of wound healing. The compounds described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: formula (I), wherein the substituents are as described.

LIGHT-EMITTING COMPOSITION

Light-Emitting Compound A composition comprising a light-emitting compound having a peak wavelength of at least 650 nm and a material comprising a group of formula (I): wherein Ar1, Ar2 and Ar3 in each occurrence are indep

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.